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Mu¨ller cells are themajor glia of the retina that serve numerous functions essential to retinal homeostasis, yet the contribution ofMu¨ller
glial dysfunction to retinal diseases remains largely unknown. We have developed a transgenic model using a portion of the regulatory
region of the retinaldehyde binding protein 1 gene for conditional Mu¨ller cell ablation and the consequences of primary Mu¨ller cell
dysfunction have been studied in adult mice. We found that selective ablation of Mu¨ller cells led to photoreceptor apoptosis, vascular
telangiectasis, blood–retinal barrier breakdown and, later, intraretinal neovascularization. These changes were accompanied by im-
paired retinal function and an imbalance between vascular endothelial growth factor-A (VEGF-A) and pigment epithelium-derived
factor. Intravitreal injection of ciliary neurotrophic factor inhibited photoreceptor injury but had no effect on the vasculopathy. Con-
versely, inhibition of VEGF-A activity attenuated vascular leak but did not protect photoreceptors. Our findings show that Mu¨ller glial
deficiency may be an important upstream cause of retinal neuronal and vascular pathologies in retinal diseases. Combined neuropro-
tective and anti-angiogenic therapies may be required to treat Mu¨ller cell deficiency in retinal diseases and in other parts of the CNS
associated with glial dysfunction.
Introduction
Mu¨ller cells are specialized glia that serve numerous functions
essential to retinal homeostasis. Playing a central role in retinal
glucose metabolism, they are intimately connected to photore-
ceptors and other neurons, which they protect through the
uptake and degradation of glutamate through the glutamate as-
partate transporter, as well as by release of neurotrophic factors
and secretion of the antioxidant, glutathione (Bringmann et al.,
2006). Mu¨ller cells are also involved in the formation and main-
tenance of the inner blood–retinal barrier (BRB), which consists
of tight junctions between endothelial cells and also depends on
the surrounding glia to maintain a precisely regulated microen-
vironment for neuronal activity (Erickson et al., 2007). Mu¨ller
cells likely provide an antiproliferative condition in the healthy
retina by releasing anti-angiogenic factors such as pigment
epithelium-derived factor (PEDF) and thrombospondin-1
(Bringmann et al., 2006; Abukawa et al., 2009). Thus Mu¨ller cell
dysfunction may result in an imbalance between anti-angiogenic
and pro-angiogenic factors, leading to BRB breakdown and an-
giogenesis (Bringmann et al., 2009; Ali et al., 2011).
Mu¨ller cells are a potential key player in retinal diseases such as
diabetic retinopathy (DR) and macular telangiectasia type 2
(MacTel-2) (Barber et al., 2000; Fletcher et al., 2007; Powner et
al., 2010; Sallo et al., 2011). Diabetes induces Mu¨ller cell abnor-
malities including increased expression of glial fibrillary acidic
protein (GFAP), reduction of glutamine synthetase (GS), and
decreased activity of the glutamate transporter (Bringmann et al.,
2006). Mu¨ller glial alterations have been reported to precede
overt retinal neuronal and vascular pathologies in DR (Barber et
al., 2000; Fletcher et al., 2007). MacTel-2 was initially distin-
guished clinically by vascular changes including right-angled
venules, vascular telangiectasis, and leak as well as deep retinal
neovascularization arising from the retinal vasculature (Gass and
Blodi, 1993; Yannuzzi et al., 2006). Recent studies, however, in-
dicate that loss of vision in MacTel-2 is a result of photoreceptor
degeneration or loss (Charbel Issa et al., 2010; Ooto et al., 2011).
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Histological analysis of an eye from a MacTel-2 patient revealed
prominent loss of Mu¨ller cell markers in the central retina
(Powner et al., 2010).
Most previous studies on the interrelationships betweenMu¨l-
ler glial dysfunction and retinal pathologies have relied on animal
models in which Mu¨ller glial dysfunction was a secondary effect
of retinal injury. The precise link betweenMu¨ller cell dysfunction
and retinal pathology, however, remains unclear. To examine the
consequences of primary Mu¨ller glial deficiency in the retina, we
generated an inducible transgenic model using a portion of the
regulatory region of the retinaldehyde binding protein 1 (Rlbp1)
gene as a cell-specific promoter along with a Cre/Lox-P approach
for Mu¨ller cell-specific gene targeting. The resultant Rlbp1-
CreER transgenic mice were crossed into Rosa-DTA176 mice, a
transgenic line carrying an attenuated form of the diphtheria
toxin fragment A (DTA176) gene, for conditional Mu¨ller cell
ablation. Our findings demonstrate that Mu¨ller glia dysfunction
may have a so far unappreciated role and may provide a mecha-
nistic link between neuronal damage and vascular pathology in
retinal diseases.
Materials andMethods
Transgene construction for generating Rlbp1-CreER transgenic mice. Ex-
periments were approved by the University of Sydney Animal Ethics and
Biosafety Committees. A 3 kb fragment of the Rlbp1 gene, previously
shown to drive Mu¨ller cell-specific gene expression (Va´zquez-Chona et
al., 2009), was amplified from C57BL6 genomic DNA using Phusion
high-fidelity DNA polymerase (New England BioLabs). The forward
primer (CATGGAGGAGTTAATTAAACGCGTAAGGTGGGCTGCT-
TGG) contained the restriction enzyme sites Pac1 and Mlu1 for subse-
quent cloning and a sequence in 677 bp upstream of the exon 1 of the
Rlbp1 gene. The reverse primer (CACTGAGTCGACCATGGTTTCTG-
CAAGTTGTGACTTCTGTAGACACCAAGA) contained a Sal1 restric-
tion enzyme site, a Kozak-ATG sequence (see Fig. 1A) and a sequence in
exon 2 of the Rlbp1 gene. The PCR product was agarose gel purified and
cloned into a previously described plasmid (ref PMID: 19850870) using
the Pac1 and Sal1 restriction sites. A linear 7 kb transgene fragment (Fig.
1A) from this plasmid was used to produce Rlbp1-CreER transgenic
mice by pronuclear injection into single-cell C57BL/6J CBA embryos,
which were then transplanted into pseudopregnant females.
Genotyping Rlbp1-CreER transgenic mice. Transgenic animals were
screened by PCR unique to the mouse Rlbp1 gene. The set of primers 1
and 2 were as follows: primer 1-forward CCTCACAGCGGTCA
CTTTTGGTAG and reverse GGAGGGCAGGCAGGTTTTGGTG,
primer 2-forward CACAGCGGTCACTTTTGGTAGATA and reverse
GCGCAGCAGGGTGTTGTAGG. Using these two sets of primers, 624
and 1100 bp PCR products were detected specifically in Rlbp1-CreER
transgenic mice only.
Crossing Rlbp1-CreER mice into Rosa-LacZ and Rosa-DTA176 trans-
genic lines. Rlbp1-CreER transgenic mice were crossed into Rosa-LacZ
reporter mice (The Jackson Laboratory; Stock# 003474) for tamoxifen
(TMX)-induced LacZ expression and into Rosa-DTA176 mice for con-
ditional Mu¨ller cell ablation. To analyze the Cre-induced LacZ or
DTA176 gene expression, offspring received daily intraperitoneal injec-
tion of TMX (3 mg per dose, dissolved in sunflower oil) at 6–8 weeks of
age for 2 or multiple days. To localize LacZ gene expression, Rlbp1-
CreER-lacZ mice were killed 4 d after the last TMX injection, their eyes
fixed in 0.25% glutaraldehyde for 1 h. Cryosections were produced for
5-bromo-4-chloro-3-indolyl--D-galactopyranoside) staining to detect
-galactosidase (-gal) activity.
Cryosection and flat-mount immunohistochemistry. Eyes were briefly
fixed in 4% paraformaldehyde (PFA) for 5 min and then anterior seg-
ments were removed. After postfixation in 4%PFA for 1 h, eye cups were
either transferred to PBS containing 30% sucrose and then embedded in
optimal cutting temperature compound for cryosection immunohisto-
chemistry (IHC), or placed in PBS for retinal flat-mount IHC. For cryo-
section IHC, frozen sections were blocked with 5% normal goat serum
and incubated with an antibody to GS (1:100; Millipore Bioscience Re-
search Reagents), cleaved-caspase 3 (1:100; Cell Signaling Technology),
SOX9 (1:200; Millipore Bioscience Research Reagents), GFAP (1:250;
Dako), collagen IV (1:250; AbD serotec), smooth muscle actin (SMA;
1:20; Dako), CD31 (1:50; BD), or vascular endothelial growth factor-A
(VEGF-A; 1:50, Santa Cruz Biotechnology). Bound antibodies were de-
tected with Alexa Fluor 488- or 594-conjugated goat or donkey second-
ary antibodies (1:1000; Invitrogen).
For flat-mount staining, dissected eye cups were fixed in 4% PFA for
1 h and then placed in PBS at4°C overnight. On the next day, retinas
were isolated, rinsed in PBS, and permeabilized with 1% Triton X-100
containing 5% normal goat serum blocking solution for at least 2 h.
Retinas were incubated in 100 l of solution containing fluorescence-
conjugated peanut agglutinin (PNA, 10 g/ml; Invitrogen) to label cone
photoreceptor outer segments (POS) or Griffonia simplicifolia isolectin
B4 (IB4; 10g/ml; Sigma) for retinal vessels in 0.1 M PBSwith 1% bovine
serum albumin (BSA) and 0.5% Triton X-100 overnight at4°C. PNA-
labeled images were processed and quantitatively analyzed using
computer-based image analysis softwarewith customizedmacroroutines
as described previously (Guidolin et al., 2004; Shen et al., 2006).
Todirectly correlate retinal vascular abnormalitieswith photoreceptor
injury, retinas were incubated with a mixture consisting of Alexa Fluor
594-conjugated IB4 (10g/ml; Invitrogen) and fluorescence-conjugated
PNA (10 g/ml; Invitrogen). To correlate retinal vascular changes with
alterations of tight junction protein claudin-5 expression, retinas were
incubated with a mixture consisting of Alexa Fluor 488-conjugated IB4
(10 g/ml; Invitrogen) and a rabbit polyclonal antibody to claudin-5
(1:100; Zymed). The bound antibody was detected with Alexa Fluor
594-conjugated secondary antibody (1:1000; Invitrogen). Retinas were
flattened onto Superfrost-plus microscope slides and mounted for con-
focal laser scanning microscopy.
Terminal deoxynucleotidyl transferase dUTP nick end labeling. Frozen
sections were examined for apoptotic cells with Roche in situ cell death
detection kit (CatalogNo. 11684795910; RocheApplied Science) accord-
ing to instructions and followed by propidium iodide nuclear counter-
staining (10 g/ml; Invitrogen) for confocal laser scanning microscopy.
Light and electron microscopy. For light microscopy, eye cups were
fixed in 4% PFA for 2 h and embedded in paraffin. Hematoxylin and
eosin staining was performed on 5 m paraffin sections. For electron
microscopy, eye cups were fixed in 2% PFA plus 2.5% glutaraldehyde in
0.1 M cacodylate buffer for 24 h followed by rinsing in 0.1 MNa cacodylate
buffer for 2 h. The eye cups were then postfixed in 1% OsO4 in 0.1 M
cacodylate buffer for 2 h, followed by another 1 h wash and dehydration
with graded ethanol solutions. Samples were incubated overnight in a 1:2
mixture of propylene oxide andEpon/Araldite (Sigma-Aldrich) and then
placed in 100% resin followed by embedding. The blocks were sectioned
for high-magnification electron microscopy.
Electroretinography. Full-field electroretinography (ERG) was per-
formed to assess retinal function as previously described (Moxon-Lester
et al., 2009). Briefly, mice were dark adapted overnight, anesthetized by
intraperitoneal injection of a mixture of xylazine (15 mg/kg), ketamine
(75 mg/kg), and acepromazine (2 mg/kg) and the pupils dilated with 1%
tropicamide and 2.5% phenylephrine. A single- or twin-flash paradigm
was used to elicit mixed (rod and cone) or isolated cone responses, re-
spectively. Flash stimuli for mixed responses were provided by a photo-
graphic flash unit (Mecablitz 60CT4; Metz), over a stimulus intensity
range of 4.2 to 3.0 log cd.s.m2. Interstimulus interval was increased
from 2 s for the lowest intensities to 5 min for the highest intensities to
allow complete recovery of the b-wave between stimuli. Isolated cone
responses were obtained over the same intensity range following a rod-
saturating stimulus of 2.1 log cd.s.m2 given 400 ms before the test
stimulus. This short interval after a rod-saturating flash does not allow
recovery of rod function, thereby revealing cone-only responses. Isolated
rod responses were obtained by digital subtraction of the cone response
from the mixed response at each stimulus intensity. The a-wave ampli-
tude was measured from the baseline to the trough of the a-wave re-
sponse and the b-wave amplitude was measured from the trough of the
a-wave to the peak of the b-wave. Data were expressed as the mean wave
amplitude  SEM (V). Two-factor repeated measures ANOVA was
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performed to compare the responses from transgenic andwild-typemice
over the flash stimulus range. The amplitudes of the inner retinal–de-
rived oscillatory potentials (OPs), which are superimposed on the rising
phase of the b-wave, were calculated as described by Bui et al. (2002).
Fundus fluorescein angiography. Fundus fluorescein angiography (FA)
were performed using a modified clinical fundus camera (Topcon TRC-
50VT) mounted with a 40D lens as previously described (Shen et al.,
2010).
Intravitreal injection of ciliary neurotrophic factor (CNTF) and
VEGFB20-4.1.1. Intravitreal injection of ciliary neurotrophic factor
(CNTF; Sigma, #C3710) and VEGFB20-4.1.1 (Genentech) was per-
formed using a 32-gauge needle attached to a Hamilton syringe. One
microliter solution was injected intravitreally and the contralateral eye
received balanced salt solution (BSS) containing the same concentration
of BSA as a control in each mouse.
Quantitative measurement of retinal vascular permeability. BRB break-
down was quantitatively evaluated by measuring retinal vascular perme-
ability to fluorescein isothiocyanate (FITC)-conjugated dextran as
described previously with slight modifications (Miyahara et al., 2004;
Shen et al., 2010). In brief, after deep anesthesia, FITC-dextran (MW
70 kDa, 25 mg/kg; Sigma) was injected intravenously. Fifteen to twenty
minutes after injection, the chest cavity was opened and a perfusion
cannula was introduced into the aorta. A blood sample was collected
immediately before perfusion. After achieving drainage from the right
atrium, each mouse was perfused with saline (500 ml/kg) to clear the
remaining intravascular dextran. The blood sample was centrifuged at
7000 rpm for 20 min at 4°C, and the supernatant was diluted at 1:1000.
After perfusion, the retinas were carefully removed, weighed, and ho-
mogenized to extract the FITC-dextran in 0.25 ml of water. The extract
was processed for fluorescence reading using a spectrofluorometer with
excitation 485 nm and emission 538 nm. Corrections were made by
subtracting the reading of water blank. For normalization, the amount of
FITC-dextran within the retina was divided by the retinal weight and by
the concentration of FITC-dextran in the plasma. BRB breakdown was
calculated using an equation described previously (Miyahara et al., 2004;
Shen et al., 2010), with the results being expressed inmicroliters per gram
per hour.
Western blot. ForWestern blot, proteins were be extracted from retinas
and their concentrations determined by DC protein assay. Equal
amounts of proteins were subjected to SDS-PAGE, transferred to a poly-
vinylidene difluoride membrane for Western blot. Membranes were
probed with antibodies to GFAP (mouse monoclonal, 1:5000; Neo-
marker), VEGF (mouse monoclonal, 1:5000; Abcam), and PEDF (goat
polyclonal, 1:200; R&D Systems). After incubation with secondary anti-
bodies conjugated with horseradish peroxidase, protein bands were vi-
sualized using the G:Box BioImaging systems and quantified using the
Figure1. Generation of transgenic (TG)mice for conditionalMu¨ller cell ablation.A, Schematic presentation of the 7 kbMluI fragment used to generate Rlbp1-CreER TGmice.B, C, LacZ expression
in Mu¨ller cells (arrows) 4 d after various doses of TMX induction in Rlbp1-CreER-LacZ mice. D–G, Immunostaining for GS in wild-type (WT; D) and Rlbp1-CreER-DTA176 mice (E–G) after four
consecutive doses of TMX treatment. Arrows (F,G) point to regionswith the broken OLMdue to loss ofMu¨ller cells.H, Quantitative analysis of Mu¨ller cell loss over time. *p 0.05, †p 0.01; both
versus day 0, respectively; n 8–10 per time point. I,K, L, TUNEL staining (green) showed that apoptotic cells were confined to the INL 1 d after TMX treatment (I ), followed later by awave of cell
death in the ONL (K, L). Sectionswere counterstainedwith propidium iodide. J, Double labeling for GS (red) and TUNEL (green) confirmed that apoptotic cells (arrows) in the INLwereMu¨ller cells 1 d
after TMX treatment.M, Quantitative analysis of TUNEL-positive cells in the INL and ONL between 1 and 28 d after TMX treatment. *p 0.01, ‡p 0.05, both versus day 0; †p 0.01, versus 1 d;
n6–8 in eachgroup.N1–N3, Colocalization of a cleaved-caspase 3 cellwith aGSMu¨ller cell in the INL1dafter TMX induction. The cleaved-caspase 3 cell possesses the typicalmorphology
of Mu¨ller glia (arrows in N1 and N3). O–R, immunostaining using SOX9 as a Mu¨ller nuclear marker (green, arrows) and Hoechst nuclear counterstaining (blue) showing that Mu¨ller cell loss in the
INL was well correlated with photoreceptor damage in the ONL. GCL, ganglion cell layer; RPE, retinal pigment epithelium. Scale bars: B–G, I, K–L, N–R, 50m; J, 25m.
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GeneTools image scanning and analysis package. Protein expression was
normalized to /-tubulin (rabbit polyclonal, 1:2000; Cell Signaling
Technology), which serves as a loading control.
Statistics. Results are expressed as mean  SEM. Data were analyzed
using ANOVA for multiple comparisons (GB-STAT v9.0; Dynamic Mi-
crosystems) or paired t test with a p value0.05 accepted as statistically
significant.
Results
Generation of transgenic mice for conditional Mu¨ller
cell ablation
We used a Cre/Lox-P approach to produce inducible transgenic
mice for Mu¨ller cell-specific gene targeting. This construct con-
tained a 2.6 kb portion of the regulatory region of the Rlbp1 gene,
which consists of the putative Rlbp1 promoter, the first two exons
and the first intron of the Rlbp1 gene (Fig. 1A) that drives robust
Mu¨ller cell-specific gene expression (Va´zquez-Chona et al.,
2009). After crossing Rlbp1-CreERmice into Rosa-LacZ reporter
mice (Maxwell et al., 1987;Wu et al., 2006), TMXgiven at 6weeks
of age induced LacZ expression in cells with the morphology of
Mu¨ller glia showing radial processes extending from the inner
limiting membrane (ILM) to the outer limiting membrane
(OLM) and cell bodies in the inner nuclear layer (INL) (Fig.
1B,C). LacZ expression was more extensive after higher doses of
TMX (Fig. 1B,C). No LacZ expression was detected in the retinal
pigment epithelium (RPE) or any other retinal cells (Fig. 1B,C).
LacZ expression was not found in the brain (data not shown).
After crossing Rlbp1-CreER mice into Rosa-DTA176 mice,
selective Mu¨ller cell ablation was observed as early as 1 d and
became stable 14 d after TMX treatment in adult mice (Fig. 1D–
H). Thiswas revealed by IHC forGS,which showedpatchy loss of
Mu¨ller cells in Rlbp1-CreER-DTA176 transgenic mice (Fig. 1E–
G). Mu¨ller cell loss and subsequent retinopathy were only ob-
Figure 2. Changes in retinal ultrastructure after conditional Mu¨ller cell ablation. A–H, Electron micrographs showing ultrastructural changes 14 d after TMX treatment. A–D, Wild-type retina.
E–H, Mu¨ller cell ablation induced by TMX in transgenic mice resulted in reduced electron-dense end feet of the Mu¨ller glia in the ILM (white asterisks in E), loss of Mu¨ller somata in the INL (black
asterisks in F ), absence of the OLM (white arrows in G), and protrusion of photoreceptor nuclei (black arrows in G andH ) into the subretinal space, but the RPE remained relatively normal (H ). M,
Mu¨ller cells; ONLouter nuclear layer, OS, photoreceptor outer segments; BM, Bruch membrane; CC, choroidal capillaries. Scale bars: 10m.
Figure 3. Impaired retinal function and photoreceptor damage after Mu¨ller cell ablation. A, B, Mu¨ller cell ablation resulted in abnormal ERG responses in transgenic (TG) mice, characterized by
reduced amplitudes of both a-wave (A) and b-wave (B) responses. ERG was measured at flash intensities ranging from4.2 to3.0 log cd.s.m2. C, Representative ERG showing maximum
responsesmeasured inwild-type (WT)andTGmice.D, Rodand cone responses toa twin-flashparadigmandchanges inmaximumOPs. TheERGwasexaminedat6weeks after four consecutivedoses
of TMX treatment. *p0.01; †p0.05, TG versusWT,n8 in eachgroup.E–H, Retinalwhole-mount stainingwith PNA for conePOS. I, Quantitative analysis of conePOSusing customized image
analysis software (37, 38). *p 0.01 versus day 0; †p 0.01 versus 7 d; n 6–8 in each group. Scale bars: E–H, 100m.
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served in TMX-treated Rlbp1-CreER-DTA176 transgenic mice
but not in controls including (1) wild-type mice crossed with
Rosa-DTA176 mice and treated with TMX, (2) R1bp1-CreER-
LacZ mice treated with TMX, (3) R1bp1-CreER-DTA176 mice
treated with vehicle only (sunflower oil), and (4) R1bp1-CreER-
DTA176 mice without TMX treatment (data not shown).
Cell apoptosis, detected by terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) staining, occurred pre-
dominantly in the INL 1 d after TMX treatment in transgenic
mice (Fig. 1 I, J,M). Double-label staining using GS and TUNEL
staining showed colocalization of Mu¨ller cell bodies and apopto-
tic cells in the INL (Fig. 1 J). The Mu¨ller cell-specific killing 1 d
after TMX induction was further confirmed by double-label IHC
using cleaved-caspase 3 as an early marker of cell apoptosis in
combination with the Mu¨ller cell-specific marker of GS (Fig.
1N1–N3). Following Mu¨ller cell death in the INL, a wave of cell
apoptosis was observed in the outer nuclear layer (ONL) but not
the other retinal layers (Fig. 1M). After gradually appearing from
day 3, the number of apoptotic cells in the ONL peaked between
5 d and 14 d then decreased 28 d after TMX treatment (Fig.
1K–M). Furthermore, we used SOX9 as a nuclear marker to
evaluate the relationship between Mu¨ller cell loss and photore-
ceptor injury. Our data showed that the areas of loss ofMu¨ller cell
bodies in the INL were closely associated with photoreceptor
injury in the ONL (Fig. 1O–R). Asmouse cells do not have recep-
tors for DTA, leak of DTA176 from dead Mu¨ller cells is unlikely
to result in bystander effects on other retinal cells (Maxwell et al.,
1987; Wu et al., 2006). To further exclude the bystander effect of
extracellular DTA176, we extracted proteins from transgenic ret-
inas 1 d and 7 d after TMX treatment. Intravitreal injection of
retinal homogenates (2 mg/ml protein concentration) in wild-
typemice did not induce damage to the retinal structure, nor was
cell apoptosis detected when examined 7 d after injection (data
not shown).
Ultrastructural studies of wild-type mice treated with TMX
showed a dense ILM with regular distribution of Mu¨ller cell
bodies in the INL, an intact OLM and well organized POS (Fig.
2A–C). Two weeks after TMX treatment, transgenic mice de-
veloped loss of the electron-dense end feet of Mu¨ller cells in
the ILM, loss of Mu¨ller cell bodies in the INL, disruption of the
OLM, protrusion of photoreceptor cell bodies into the sub-
retinal space, and disorganized POS in areas of Mu¨ller cell
ablation (Fig. 2E–G). RPE cells appeared unaffected in areas
with photoreceptor damage in transgenic retinas compared
with wild-type controls (Fig. 2D,H ).
Photoreceptor damage and impaired retinal function after
conditional Mu¨ller cell ablation
Weused flash ERG to assess the functional consequences ofMu¨l-
ler cell ablation. Six weeks following TMX treatment, transgenic
mice showed significant reduction in the a-wave response at flash
intensities greater than 0.6 log cd.s.m2 and of the b-wave
Figure4. Mu¨ller cell ablation inducesBRBbreakdown.A, Normal retinal vasculature inwild-type (WT)mice3months after TMX treatment.B, Diffuse vascular leakage in transgenic (TG)mice12d
after TMX treatment. C–E, Intense focal vascular leakage appeared from 2 months and persisted for at least 5 months after TMX treatment in TG mice. F, Scales used for grading vascular leakage
revealed by FA: “0,” normal pattern of fluorescein filling with no vascular leakage; “1,” readily identifiable lesions showing diffuse leakage but without intense focal vascular leakage; “2,” intense
focal vascular leakage appears but the lesion number3; “3,” 4–6 lesions with intense focal vascular leakage; and “4,”6 lesions with intense focal vascular leakage.G, Graded vascular leakage
in TGmice from1 to 16weeks after TMX-inducedMu¨ller cell ablation.H, Quantitativemeasurement of retinal vascular permeability to fluorescence-labeled dextran 12 d after five consecutive doses
of TMX treatment. *p 0.05, TG, n 12;WT controls, n 18. I, Retinal vascular permeability 5months after various doses of TMX treatment. *p 0.05; **p 0.01, TG versusWT controls; †p
0.01, 2 TMX versus 5 TMX; n 10–12 in each group.
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response at flash intensities greater than3.0 log cd.s.m2 (Fig.
3A,B). With the maximum stimulation intensity (3.0 log
cd.s.m2), the amplitudes of both a- and b-waves in transgenic
micewere significantly reduced to 52.8 and 58.7%of the values in
wild-type controls, respectively (Fig. 3A–C). Maximum OP am-
plitudes in transgenic mice were reduced to 62% of wild-type
control values, but this difference did not reach statistical signif-
icance (Fig. 3D, p  0.055). Using a twin-flash paradigm and
digital subtraction, we isolated the cone-derived waveform from
the rod response and found that both rod- and cone-derived
b-waves were affected by Mu¨ller cell ablation (Fig. 3D).
Since results from studies on cell apoptosis, retinal ultrastruc-
ture, and ERG suggested that Mu¨ller cell ablation affects photo-
receptors, we further examined photoreceptor damage using
retinal flat mounts after PNA staining. Wild-type mice treated
with TMX showed even labeling of cone POS (Fig. 3E). Patchy
loss of cone POS was found in transgenic retinas, which pro-
ceeded for 14 d and became relatively stable 28 d after Mu¨ller
cell ablation induced by TMX (Fig. 3F–I ), which was consis-
tent with the dynamics ofMu¨ller cell loss revealed by IHC (Fig.
1E–H,P–R).
Selective Mu¨ller cell ablation led to BRB breakdown
We next tested whether Mu¨ller cell ablation caused BRB break-
down. Diffuse fluorescein leakage was commonly observed dur-
ing fluorescein angiography between 1 and 2 weeks after TMX
treatment, with areas of intense focal vascular leak developing
after 2 months and then persisting for at least 5 months in trans-
genic mice (Fig. 4A–E). Semiquantitative analysis revealed that
31% of eyes developed lesions with intense focal vascular leakage
(graded with a score of “2” or over; Fig. 4F,G) between 4 and 7
weeks and 36% between 8 and 10 weeks increasing to 80% at 11
and 16 weeks after TMX-induced Mu¨ller cell ablation (Fig. 4G).
Quantitative analysis of BRB breakdown showed that the retinal
vascular permeability to fluorescein-labeled dextran was signifi-
cantly increased 12 d after TMX treatment in transgenic mice
compared with wild-type controls (Fig. 4H). By 5 months after
TMX treatment, a dose-dependent response to the numbers of
TMX injections was found, with retinal vascular permeability
increased to 125% (p 0.05) after two doses of TMX and 189%
(p  0.01) after five doses in transgenic mice compared with
wild-type controls (Fig. 4 I).
Development of intraretinal vascular abnormalities and deep
retinal neovascularization
Retinal flat-mount staining using IB4 showed smooth and well
defined retinal vessels in wild-type mice (Fig. 5A) while trans-
genic animals developed vascular telangiectasis as early as 7 d
(Fig. 5B) and vascular tufts were frequently observed from 2
months after TMX treatment (Fig. 5C,D). IHC revealed amarked
reduction in claudin-5 immunoreactivity on microvessels that
were developing vascular tufts in transgenicmice (Fig. 5E–H). To
identify the location of vascular leakage afterMu¨ller cell ablation,
we performed immunostaining for mouse IgG. In wild-type ret-
ina, the immunoreactivity for mouse IgG was sharply restricted
to vessels within the inner retina (Fig. 5I). Diffuse IgG immuno-
reactivity was observed around deep retinal vessels as early as 7 d
after TMX treatment (Fig. 5J, arrows) and became more intense
at 2 months when abnormal vessels had appeared in the deep
retina (Fig. 5K, arrows) in transgenic mice. The growth of deep
Figure 5. Mu¨ller cell ablation results in vascular telangiectasis and deep retinal neovascularization. A–D, Retinal flat-mount staining with IB4 showing increased vascular tortuosity 7 d (B) and
intraretinal vascular tufts 2 months (C and D; D is a higher power image of the squared area in C) after TMX treatment in transgenic (TG) mice. E–H, Double labeling for IB4 (green, E and G) and
claudin-5 (red,FandH ) showing reductionof claudin-5 in the regionof vascular tufts. I–L, Immunostaining formouse IgG showing that vascular leakagewaspredominantly localized todeep retinal
vessels in TGmice.K, L, Immunostaining formouse IgG (K ) and collagen IV (L) showing growth of abnormal vessels (arrows) in the outer retina 2months afterMu¨ller cell ablation. GCL, ganglion cell
layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bars: A–C, 200m; E–H, 100m; D, J–L, 50m.
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retinal new vessels 2months afterMu¨ller cell ablationwas further
confirmed by IHC for collagen IV (Fig. 5L, arrows).
Mapping retinal vascular changes and photoreceptor damage
withMu¨ller cell loss
Wild-type mice treated with TMX demonstrated smooth and
well defined superficial, intermediate, and deep vascular net-
works overlying a regular and dense arrangement of POS (Fig.
6A). In transgenic mice, tortuous retinal vessels were observed at
all three levels of the retinal vascular network and accompanied
by patchy loss of POS 7 d after TMX treatment (Fig. 6B). After 2
months, loss of retinal capillaries was noted in regions of POS loss
where growth of abnormal vessels was detected (Fig. 6C, arrows).
By 5months, pronounced loss of retinal capillaries and growth of
abnormal vessels were commonly observed in transgenic mice
(Fig. 6D, arrows). We performed double labeling to map Mu¨ller
cell loss with photoreceptor damage and retinal vascular changes.
Similar to what we observed in Figure 1,Q and R, IHC on frozen
sections showed that the extent of photoreceptor injury corre-
lated well with the scale of Mu¨ller cell loss (Fig. 6E–H), and that
the growth of deep retinal new vessels (Fig. 6K2,L2, arrows) only
occurred in areas of Mu¨ller cell ablation2 months after TMX-
induced Mu¨ller cell ablation (Fig. 6 I–L).
Changes in histology
Disruption of retinal structure and development of deep retinal
neovascularizationwere confirmed by light (Fig. 7A–D) and elec-
tron microscopy (Fig. 7E). In eyes where neovascularization had
developed, ultrastructural studies also revealed RPE clumping,
proliferation, and migration into regions where new vessels oc-
curred, but Bruch’s membrane (BM) appeared intact (Fig. 7E),
indicating that the new vessels originated from the inner retina
rather than choroidal capillaries.
Effects of intravitreal injection of CNTF on photoreceptor
injury and BRB breakdown
Since Mu¨ller cells are a significant source of neurotrophic
factors (LaVail et al., 1992; Cayouette and Gravel, 1997; Walsh
et al., 2001), we reasoned that Mu¨ller cell ablation would cause
photoreceptor apoptosis as a result of the loss of support from
trophic factors. We tested this hypothesis by performing in-
travitreal injection of recombinant CNTF. Intravitreal CNTF
had no effect on wild-type retinas (Fig. 8A,B) but significantly
reduced both the area of cone POS loss and the number of
apoptotic cells in the ONL between 7 and 10 d after TMX
treatment (Fig. 8C–F ) in transgenic mice. We further exam-
ined whether CNTF treatment also inhibited BRB breakdown.
Quantitative measurement of retinal permeability to FITC-
dextran and FA showed that CNTF treatment had no effect on
BRB breakdown when administrated either soon after Mu¨ller
cell ablation (4 d after TMX; Fig. 8G), or later after lesions of
focal intense vascular leak had developed (4 months after
TMX; Fig. 8H).
Figure 6. Mapping retinal vascular changes and photoreceptor injury with patchy loss of Mu¨ller cells. A–D, Retinal flatmounts were subject to double labeling using IB4, red for vessels and PNA
for cone POS (green). Projected imageswere generated after scanning retinal flatmountswith the ganglion cell layer up at superficial (0m), intermediate (4m), and deep vascular plexuses (12
m)andat the level of POS (22m).A,Wild-type (WT)mice showed smooth andwell defined retinal vascular complexes, accompaniedby regular anddensedistributionof POS.B, Sevendays after
TMX treatment, transgenic (TG)mice showed increased vascular tortuosity at all three levels and patchy loss of POSwas visible. C, By 2months, TGmice demonstrated increased vascular tortuosity
and loss of POS and retinal capillaries. Budding new vessels (arrows) are detected in areas with photoreceptor damage. D, By 5 months, further loss of retinal capillaries and widespread abnormal
vessels (arrows)were observed in areaswith severe photoreceptor damage.E–H, Immunostaining for GS (green) andnuclear counterstainingusingpropidium iodide (PI, red) to correlateMu¨ller cell
loss with photoreceptor damage. I–L, Double immunostaining for GS (green, I1–L1) and collagen IV (Col-IV; red , I2–L2) to correlate Mu¨ller cell loss with the growth of deep retinal neovascular-
ization (arrows in K and L). Note new vessel growth from inner retina into deeper retina in L (arrows). Scale bars: A–D, 100m; E–L, 50m.
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Imbalance between VEGF-A and PEDF expression after
Mu¨ller cell ablation
Since an imbalance between angiogenic and angiostatic factors is
associated with BRB breakdown and retinal angiogenesis,
we tested whether altered expression of VEGF-A and PEDF oc-
curred after TMX-induced Mu¨ller cell ablation. Upregulation of
VEGF-A was observed as early as 7 d after TMX treatment and
persisted at 4 months, but significant reduction in PEDF expres-
sion was only detected 4 months after TMX when lesions of in-
tense focal vascular leakage had developed (Fig. 9A,B). IHC
showed persistent upregulation of VEGF-A around deep but not
superficial retinal vessels 7 days and 4 months after TMX treat-
ment (Fig. 9C), which was accompanied by reduction of PEDF
expression in areas ofMu¨ller cell ablation (Fig. 9D). Double-label
IHC indicated that the increased expression of VEGF-A around
deep retinal vessels was more likely from pericytes than from
vascular endothelial cells (Fig. 9E,F).
Effects of intravitreal VEGFB20–4.1.1 on BRB breakdown
and photoreceptor injury
We next tested whether inhibition of VEGF-A activity reduced
retinal vascular leakage. Intravitreal injection of VEGFB20-4.1.1,
a novel VEGF antibody that binds both human and murine
VEGF-A (Liang et al., 2006), inhibited BRB breakdown when the
injection was performed 4 d after TMX treatment, and evalua-
tionswere conducted 6 d later (Fig. 10A). After injecting into eyes
where intense focal retinal vascular leakage had developed,
VEGFB20-4.1.1 dramatically inhibited the established vascular
leakage when examined 3, 7, and 35 d after injection while lesions
in eyes receiving vehicle remained relatively unchanged (Fig.
10B,C). However, anti-VEGF-A treatment did not prevent pho-
toreceptor loss in transgenic mice when VEGFB20-4.1.1 was in-
jected 4 d after TMX treatment and the loss of POS was evaluated
6 d later (Fig. 10D,E).
Discussion
In this study, we have fully characterized changes in retinal neu-
rons and vasculature after conditional Mu¨ller cell ablation in a
novel transgenic model. We demonstrate that selective ablation
of Mu¨ller cells led to neuronal damage on one hand, with photo-
receptor apoptosis, and vasculopathy on the other, including tel-
angiectasis, BRBbreakdown, and intraretinal neovascularization.
All of these features are found inmany retinal diseases such asDR
andMacTel-2. Our findings suggest thatMu¨ller glial dysfunction
may provide a common link between photoreceptor injury and
vascular pathology. The different responses of the neural and
vascular changes to neuroprotective and anti-angiogenic treat-
ments suggest that both may be required to treat the clinical
consequences of Mu¨ller cell deficiency.
We have successfully produced a transgenic model for condi-
tional Mu¨ller cell in the retina. -gal activity was exclusively ex-
pressed in Mu¨ller cells in Rlbp1-LacZ mice, thus confirming that
the regulatory region of the mouse Rlbp1 gene is sufficient to
promote robust transgene expression in a Mu¨ller cell-specific
manner (Va´zquez-Chona et al., 2009).Mu¨ller cell-specific killing
was supported by the predominant localization of apoptotic cells
to the INL 1 d after TMX treatment in Rlbp1-DTA176 transgenic
mice. Subsequent immunostaining for GS and SOX9 revealed
that patchy loss of Mu¨ller cells occurred throughout the retina
over time for 2 weeks. Mu¨ller cell ablation was further confirmed
by electron microscopy showing decreased electron-dense end
feet of the Mu¨ller glia in the ILM, loss of Mu¨ller cell bodies in the
INL, and focal loss of the OLM. DTA is a cytotoxic protein that
binds to a specific receptor on the cell surface and then is inter-
nalized by receptor-mediated endocytosis (Mitamura et al.,
1995). DTA is translocated to the cytosol where it inactivates
elongation factor 2 through ADP-ribosylation, thus inhibiting
cellular protein synthesis and inducing cell death through apo-
Figure7. Retinal structural changes in histology.A–D, Lightmicrographs fromwild-type (WT;A) and transgenic (TG;B–D) retinas. Damage to photoreceptorswas clearly visible but newvessels
were not observed in TGmice 2weeks (B) while new vessels (white arrows, C andD) appeared 2months after TMX treatment in TGmice.D, A higher power image of the squared area in C. The black
arrow inDpoints to clumpingRPE in thedisruptedarea.E, Electronmicroscopy revealed subretinal neovascularization (blackarrows)butBruch’smembrane (BM) remained intact 3monthsafter TMX
treatment. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; OS, photoreceptor outer segments; CC, choroidal capillaries. Scale bars: A–C, 50m; D, 25m; E, 10m.
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ptosis (Morimoto and Bonavida, 1992; Mitamura et al., 1995;
Ghosh et al., 2011). Because mouse cells have no receptor for
DTA (Mitamura et al., 1995), leak or Cre-independent expres-
sion of DTA176 is unlikely to result in bystander cell lethality
even if active DTA176 molecules are released from dead Mu¨ller
cells in our transgenicmice (Maxwell et al., 1987;Wu et al., 2006).
The negative findings in histology and TUNEL staining after in-
travitreal injection of retinal homogenates extracted from trans-
genicmice have further ruled out the bystander effect of DTA176
in this study.
The dynamics of photoreceptor damage is consistentwith that
of Mu¨ller cell loss between 7 and 28 d after TMX induction.
Damage to photoreceptors was demonstrated by protrusion of
the ONL into the subretinal space and loss of cone POS. The
former is likely due to focal loss of the OLM, which is the outer
end feet ofMu¨ller glia. Photoreceptor damagewas also supported
by ERG, as indicated by suppression of the a- and b-wave re-
sponses of both rods and cones in transgenic mice. These obser-
vations are consistent with previous reports that Mu¨ller cell
disruption leads to retinal dysplasia and degeneration during
postnatal development (Rich et al., 1995; Dubois-Dauphin et al.,
2000; Dyer and Cepko, 2000). Because Mu¨ller cells play a central
role in retinal glucose metabolism and in the protection of neu-
rons through the uptake and degradation of glutamate, release of
neurotrophic factors, and secretion of the antioxidants, it is likely
that disruption of these important functions by selective ablation
of Mu¨ller cells results in neuronal damage. Overall, our findings
on photoreceptor damage after Mu¨ller cell ablation reflect the
importance of Mu¨ller cells in the maintenance of photoreceptor
health and function. The fact that ganglion cells and neurons in
the inner retina were much less affected in our model, at least
based on histologic and ultrastructural analysis, suggests that
theymay receive support fromother retinal glia such as astrocytes
and, potentially, activatedmicroglia (Oliet et al., 2001; Karlstetter
et al., 2010). This warrants further investigation.
In the mature retina, Mu¨ller glia are the major source of CNTF,
which is among themost potent of trophic factors protecting retinal
neurons (LaVail et al., 1992; Cayouette and Gravel, 1997; Walsh et
al., 2001; Rhee et al., 2007). Loss of neurotrophic support fromMu¨l-
ler cells would affect the survival of neurons. Our data suggest that
photoreceptors can be rescued by supplement of CNTF in condi-
tions linked toMu¨ller cell loss or deficiency. CNTF treatment signif-
icantly reduced both the area of POS loss and the number of
photoreceptors undergoing apoptosis, thus indicating that the pho-
toreceptor injury is associated with the loss of neuroprotective fac-
tors normally produced byMu¨ller cells.
Figure 8. Effects of intravitreal injection of CNTF on photoreceptor injury (A–F ) and BRB breakdown (G, H ). A–D, CNTF (0.5 g) was injected 4 d after TMX treatment in one eye and the
contralateral eye receivedBSS containing the sameamountofBSA ineachmouse. PNAstainingwasperformed6d later.E, Quantitative analysis of PNA-stained retinalwholemounts.p0.01, CNTF
versus BSS in TGmice. F, TUNEL for photoreceptor apoptosis. CNTF or BSSwas injected 1 d after TMX treatment and TUNELwas performed 6 d after intravitreal injection. †p 0.05, CNTF versus BSS.
G, Quantitative analysis of retinal permeability to fluorescence-labeled dextran. CNTF was injected 4 d after TMX treatment and permeability was measured 7 d later. *p 0.01, WT versus TG. H,
Effects of CNTF on established retinal vascular leakage. FA was performed to confirm the development of intense focal vascular leakage 4months after Mu¨ller cell ablation and CNTF was injected 1
week later. Retinal vascular leakage was monitored by FA at 5 and 12 d after CNTF injection. Scale bars: A–D, 100m.
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Breakdown of the BRB occurred rapidly after selective Mu¨ller
cell ablation, suggesting that Mu¨ller cell loss may directly disrupt
the anatomical structure of the retinal vessels, which they closely
invest (Bringmann et al., 2006; Erickson et al., 2007). This was
supported by our finding that the tight junction protein
claudin-5 was reduced in regions where vascular tufts were form-
ing. Previously we found similar changes in the BRB and
claudin-5 expression after disrupting Mu¨ller glia by subretinal
injection of DL--aminoadipic acid, a reportedly glia-specific
toxin in rats (Shen et al., 2010). A link between glial disruption,
reduced expression of junction-associated proteins, and blood–
brain barrier breakdown has also been previously found in the
brain (Willis et al., 2004, 2007). Upregulation of VEGF-A expres-
sion was observed as early as 7 d after TMX induction and it
persisted for at least 4 months in our transgenic mice. Overex-
pression of VERGF-A was predominantly around deep retinal
vessels in the region of Mu¨ller cell ablation. Double-label IHC
indicated that the increased expression of VEGF-A was most
likely from pericytes rather than the vascular endothelium.Over-
all, our observations also reflect the importance of Mu¨ller cells in
the formation and maintenance of a healthy microenvironment
for BRB function.
Overexpression of VEGF-A has been closely linked to ocular
angiogenesis such as DR, age-related macular degeneration, and
MacTel-2 (Matsuoka et al., 2004; Jorge et al., 2007; Kovach and
Rosenfeld, 2009; Mohan et al., 2012). We found that deep retinal
neovascularization mostly occurred from 2 months after TMX-
induced Mu¨ller cell ablation. By 4 months after TMX treatment
when the majority of eyes developed deep retinal new vessels,
Mu¨ller cell ablation resulted in both upregulation ofVEGF-A and
reduced expression of PEDF, thus altering the balance between
angiogenic and angiostatic factor in regions withMu¨ller cell loss.
Our results support the hypothesis that selective Mu¨ller cell ab-
lation induces long-term deregulations of VEGF and PEDF
expression, thus contributing to the growth of deep retinal
neovascularization.
We next tested whether anti-VEGF-A therapy is effective in
inhibition of BRB breakdown induced by selective Mu¨ller cell
ablation. Our results showed that intravitreal injection of
VEGFB20-4.1.1 attenuated the retinal vascular permeability
when the VEGF antibody was injected 4 d after TMX induction
and analysis was conducted 6 d later. Furthermore, anti-VEGF-A
therapy was also effective at 4months after TMX treatment when
deep retinal neovascularization had developed. The inhibitory
effect of anti-VEGF-A therapy on BRB breakdown further con-
firms that VEGF-A overexpression plays an important role in
retinal vascular pathology caused by Mu¨ller cell loss.
Interestingly, in contrast to its protective effect on photore-
ceptors, CNTF treatment had no effect on BRB breakdown when
injected either early (4 d after TMX treatment) or later (4months
after TMX treatment) when lesions of focal intense leakage had
occurred. Similarly, VEGFB20-4.1.1 inhibited BRB breakdown
but had no effect on photoreceptor injury. These results suggest
that photoreceptor damage and retinal vascular pathology may
Figure 9. Imbalanced expression of VEGF-A and PEDF after Mu¨ller cell ablation. A, Western blot showed upregulation of VEGF-Awhile the expression of PEDF remained relatively unchanged 7 d
after Mu¨ller cell ablation. *p 0.01, TG versusWT, n 8 in each group.B, By 4months after Mu¨ller cell ablation,Western blot revealed significant upregulation of VEGF-A and downregulation of
PEDF. †p 0.05, TG versusWT controls, n 7–8 in each group. TGmice showed persistent upregulation of GFAP 7 days and 4months after Mu¨ller cell ablation, indicating that the survival Mu¨ller
cells were at a stage of reactive gliosis. C, Double-label IHC revealed that VEGF-Awasweakly expressed in the superficial retina inWT but strong immunoreactivity was detected around deep retinal
vessels (arrows) in TG retinas 7 d and4months afterMu¨ller cell ablation.D, Reduced expression of PEDF in areas ofMu¨ller cell ablation.E,F, Double-label IHC using CD31 for the vascular endothelium
and SMA for pericytes in combination and antibody to VEGF-A suggested that overexpression of VEGF-Awasmore likely frompericytes (F, small arrows) than from the vascular endothelium (E, small
arrows). Note: the superficial retinal vessels did not overexpress VEGF-A (large arrows inE andF ). GS, glutamine synthetase; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
Scale bars: C–F, 50m; the squared area in E, 30m; the squared area in F, 20m.
15724 • J. Neurosci., November 7, 2012 • 32(45):15715–15727 Shen et al. •Mu¨ller Cell Ablation and Retinal Pathology
be independent events that are caused by Mu¨ller cell loss but are
otherwise unrelated.
Results from this studymay improve our understanding of the
potential impacts of Mu¨ller cell dysfunction on retinal neurons
and vasculature in DR. It has been well established that diabetes
induces apoptosis of a variety of retinal cells including endothe-
lial cells, pericytes, neurons, and Mu¨ller cells (Hammes et al.,
1995; Barber et al., 2011; Wu et al., 2012). However, the relation-
ships between apoptosis of different classes of retinal cells and
vascular complications remain unclear. In the diabetic retina,
Mu¨ller cells actually display both apoptosis and reactive gliosis,
but the rate of Mu¨ller glial activation appears to exceed that of
apoptosis (Bringmann et al., 2006, 2009; Barber et al., 2011). Our
data indicate that patchy loss ofMu¨ller cells is sufficient to induce
photoreceptor damage, BRB breakdown and intraretinal neovas-
cularization. It is plausible that over many years of diabetes,
progressive dysfunction of retinal Mu¨ller cells may affect glu-
tamate metabolism, reduce production of trophic factors that
are important for the survival of both retinal neurons and
vascular cells, and disturb the balance between angiogenic and
angiostatic factors, thus contributing to neuronal and vascular
complications in DR.
The photoreceptor damage and retinal vasculopathy in the
transgenic model are similar to features of MacTel-2 in humans.
Optical coherence tomography has recently demonstrated a neu-
rodegenerative process inMacTel-2, with photoreceptor damage
mapped to loss of vision (Charbel Issa et al., 2010). Vascular
changes in MacTel-2 are characterized vascular telangiectasis,
leak, and deep retinal neovascularization (Gass and Blodi, 1993;
Yannuzzi et al., 2006). A recent study showed prominent loss of
Mu¨ller cell markers in the central retina after analysis of histolog-
ical changes in a donor eye from a MacTel-2 patient (Powner et
al., 2010); this finding has been confirmed in the second donor of
MacTel-2 (M. Futtiger, unpublished data). In light of the fact that
a cone-shaped zone ofMu¨ller cells acts as a critical structural and
functional support for the fovea (Gass, 1999), our observations
from the transgenic model strongly support the hypothesis that
Mu¨ller cell dysfunction is a major player in the pathogenesis of
MacTel-2.
In summary, we have shown that selectiveMu¨ller cell ablation
is sufficient to induce photoreceptor degeneration, vascular tel-
angiectasis, BRBbreakdown, and intraretinal neovascularization,
which are major features shared by a number of retinal diseases
such as DR andMacTel-2. Our findings indicate that Mu¨ller glial
Figure10. Effects of anti-VEGF-A therapywith VEGFB20-4.1.1 on BRBbreakdown (A–C) and photoreceptor injury (D, E). VEGFB20-4.1.1 (16.38g)was injected in one eye and the contralateral
eye receivedBSS containing the sameamount of BSA in eachmouse.A, Quantitativemeasurement of retinal permeability to fluorescence-labeled dextran. VEGFB20-4.1.1was injected 4 d after TMX
treatment and retinal permeability wasmeasured 6 d later. *p 0.01; †p 0.05, both TG versusWT.B, FAwas performed to confirm the development of intense focal vascular leakage 4months
afterMu¨ller cell ablation and VEGFB20-4.1.1was injected 1week later. Retinal vascular leakagewasmonitored by FA at various time points after intravitreal injection. C, Graded fluorescein leakage
3, 7, and 35d after injection of VEGFB20-4.1.1 or BSS using scales as described in Figure 4. *p 0.01, versus before injection at day 0; †p 0.01 and ‡p 0.05, anti-VEGF-A (VEGFB20-4.1.1) versus
BSS, respectively; n 18 at each time point. D, E, Analysis of PNA staining of retinal whole mounts showed anti-VEGF-A action had no effect on protecting photoreceptor injury (*p 0.01, WT
versus TG). Scale bars: D, 100m.
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deficiency may have a so far unappreciated role and be a mecha-
nistic link between neuronal and vascular pathology in retinal
diseases. This is the first study to describe that Mu¨ller glial defi-
ciency may be one of the upstream causes of retinal neural and
vascular pathologies in retinal diseases. A sustained-release for-
mulation of CNTF using encapsulated cell technology has shown
encouraging results in protecting photoreceptors in humanswith
retinal pigmentosa and age-related macular degeneration (Siev-
ing et al., 2006; Zhang et al., 2011). Anti-VEGF-A therapy has
been widely used to treat retinal vascular diseases. The clinical
implication of our findings is that a combined therapeutic ap-
proach that targets the neuropathy as well as the vasculopathy
may be required to treat diseases caused by dysfunction ofMu¨ller
cells and, potentially, other glial cells in the CNS.
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